REGENERON PHARMACEUTICALS, INC. Total Contract Liability
REGENERON PHARMACEUTICALS, INC. (REGN) had Total Contract Liability of $322.50 million as of 2021-12-31, per its 10-K filed 2022-02-07.
Discontinued › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2022-02-07
- 2021-12-31: Contract with Customer, Liability $322.50M.
| Period end | Contract with Customer, Liability |
|---|---|
| 2021-12-31 | $322.50M 10-K · filed 2022-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |